Danielle Antalffy (UBS) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Danielle Antalffy's stock ratings?

About 34% of Danielle's ratings were profitable over a one-year hold, with an average return of -11.0% per rating, measured by 13Foresight from historical prices.

Q: How is Danielle ranked?

Danielle Antalffy is ranked #2383 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Danielle Antalffy

UBS

Danielle Antalffy

UBS

Wall Street Analyst

★☆☆☆☆

#2383

on 13Foresight · ranked by our own returns

34%

Success Rate

-11.1%

Average Return

12 of 35 calls profitable · -18.2% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 34% of Danielle Antalffy's ratings turned a profit when each position was held for 1 year — averaging -11.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

43 Buy 39 Hold 5 Sell

Danielle's Stock Coverage 36 ratings · 2026-06-20

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
ABT Abbott Laboratories	Apr 20, 2026	BUY	Strong Buy +31.2% avg upside 35 analysts	$135.00 52.72% Upside	-7.8%
SYK Stryker	Mar 17, 2026	HOLD	Strong Buy +24.0% avg upside 36 analysts	$380.00 23.40% Upside	-12.8%
JNJ Johnson & Johnson	Mar 17, 2026	BUY	Strong Buy -3.5% avg upside 36 analysts	$280.00 22.67% Upside	-3.5%
ISRG Intuitive Surgical	Mar 17, 2026	HOLD	Strong Buy +29.4% avg upside 36 analysts	$550.00 35.27% Upside	-15.7%
BSX Boston Scientific	Mar 17, 2026	BUY	Strong Buy +72.9% avg upside 38 analysts	$105.00 131.90% Upside	-36.4%
SGHT Sight Sciences	Mar 06, 2026	BUY	Buy +52.9% avg upside 13 analysts	$11.00 108.33% Upside	+32.4%
TMCI Treace Medical Concepts	Mar 02, 2026	HOLD	Hold +27.0% avg upside 8 analysts	$2.25 46.31% Downside	+7.2%
PRCT PROCEPT BioRobotics	Mar 02, 2026	BUY	Buy +79.5% avg upside 16 analysts	$30.00 38.05% Upside	-13.7%
RXST RxSight	Feb 26, 2026	HOLD	Hold +132.6% avg upside 13 analysts	$9.00 90.31% Upside	-24.2%
TNDM Tandem Diabetes Care	Feb 20, 2026	HOLD	Buy +116.0% avg upside 29 analysts	$22.00 43.80% Upside	-31.2%
PODD Insulet	Feb 19, 2026	BUY	Strong Buy +79.0% avg upside 32 analysts	$400.00 174.45% Upside	-39.9%
BBNX Beta Bionics, Inc.	Feb 18, 2026	BUY	Strong Buy +51.9% avg upside 13 analysts	$24.00 72.95% Upside	+6.8%
ATRC Atricure	Feb 18, 2026	BUY	Strong Buy +58.1% avg upside 12 analysts	$55.00 90.89% Upside	-12.8%
MDT Medtronic	Feb 17, 2026	HOLD	Buy +23.5% avg upside 38 analysts	$104.00 31.09% Upside	-17.0%
BAX Baxter International	Feb 16, 2026	HOLD	Hold +49.6% avg upside 23 analysts	$19.00 4.44% Downside	+0.4%
INSP Inspire Medical Systems	Feb 13, 2026	HOLD	Buy +97.6% avg upside 20 analysts	$67.00 57.34% Upside	-29.2%
DXCM Dexcom	Feb 13, 2026	BUY	Strong Buy +38.6% avg upside 32 analysts	$95.00 31.04% Upside	+4.5%
EW Edwards Lifesciences	Feb 12, 2026	HOLD	Strong Buy +11.7% avg upside 34 analysts	$90.00 3.11% Upside	+13.4%
ZBH Zimmer Biomet Holdings	Feb 11, 2026	SELL	Buy +27.6% avg upside 37 analysts	$89.00 1.19% Upside	+6.9%
BETA BETA Technologies, Inc. Class A	Feb 09, 2026	BUY	Strong Buy +90.5% avg upside 10 analysts	$24.00 49.11% Upside	-2.9%
GKOS Glaukos	Jan 28, 2026	BUY	Strong Buy +5.5% avg upside 20 analysts	$150.00 14.78% Upside	+16.2%
ENOV Enovis	Jan 05, 2026	BUY	Strong Buy +216.5% avg upside 37 analysts	$50.00 127.61% Upside	-7.8%
INMD InMode	Nov 06, 2025	HOLD	Buy +41.7% avg upside 9 analysts	$16.00 19.42% Upside	-7.5%
BFLY Butterfly Network	Mar 28, 2023	HOLD	Strong Buy -48.9% avg upside 7 analysts	$2.25 74.69% Downside	-39.0%
LNTH Lantheus	May 17, 2022	BUY	Strong Buy -27.9% avg upside 20 analysts	$100.00 3.64% Downside	+48.0%
NPCE NeuroPace	May 12, 2022	BUY	Strong Buy +12.2% avg upside 11 analysts	$12.00 23.28% Downside	-31.9%
UTRS Minerva Surgical	May 11, 2022	BUY	Buy +799999900.0% avg upside 4 analysts	$7.00 699999899.95% Upside	·
ORGO Organogenesis Holdings	May 10, 2022	BUY	Strong Buy +375.4% avg upside 8 analysts	$13.00 432.78% Upside	-62.0%
LNSR LENSAR	May 09, 2022	BUY	Strong Buy +113.4% avg upside 4 analysts	$12.00 109.12% Upside	-62.5%
OM Outset Medical	May 05, 2022	BUY	Buy +231.0% avg upside 8 analysts	$55.00 989.03% Upside	-35.9%
BDX Becton Dickinson	May 05, 2022	HOLD	Buy +35.5% avg upside 25 analysts	$275.00 91.07% Upside	-0.9%
VCEL Vericel	May 04, 2022	BUY	Strong Buy +13.9% avg upside 16 analysts	$45.00 12.19% Upside	+5.2%
AXGN AxoGen	May 04, 2022	BUY	Strong Buy -25.7% avg upside 21 analysts	$14.00 68.72% Downside	+9.1%
CTSO Cytosorbents	May 03, 2022	BUY	Strong Buy +2611.9% avg upside 13 analysts	$5.00 1040.77% Upside	+26.6%
INGN Inogen	Jan 10, 2022	HOLD	Buy +284.8% avg upside 7 analysts	—	-26.0%
SENS Senseonics Holdings	Aug 09, 2021	HOLD	Buy +124.8% avg upside 13 analysts	$3.00 55.58% Downside	-43.1%

🔒 31 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Danielle Antalffy — Frequently Asked Questions

How accurate are Danielle Antalffy's stock ratings?

Based on the calls 13Foresight could measure, about 34% of Danielle's ratings were profitable over a one-year hold, with an average return of -11.0% per rating, or -18.1% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Danielle ranked on 13Foresight?

Danielle Antalffy is currently ranked #2383 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Danielle cover?

Danielle most recently has ratings on ABT, SYK, JNJ, ISRG, BSX, SGHT, TMCI, PRCT, RXST, TNDM, PODD, BBNX and 24 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!